478 related articles for article (PubMed ID: 21569815)
1. Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis.
Agallou M; Margaroni M; Karagouni E
Vaccine; 2011 Jul; 29(31):5053-64. PubMed ID: 21569815
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis.
Agallou M; Smirlis D; Soteriadou KP; Karagouni E
Vaccine; 2012 Jul; 30(34):5086-93. PubMed ID: 22704924
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG + Q mix protects Balb/c mice from infection.
Parody N; Soto M; Requena JM; Alonso C
Parasite Immunol; 2004; 26(6-7):283-93. PubMed ID: 15541032
[TBL] [Abstract][Full Text] [Related]
4. Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells.
Carrión J; Folgueira C; Alonso C
Vaccine; 2008 May; 26(20):2537-44. PubMed ID: 18400342
[TBL] [Abstract][Full Text] [Related]
5. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides.
Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E
Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073
[TBL] [Abstract][Full Text] [Related]
6. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major.
Bhaumik S; Basu R; Sen S; Naskar K; Roy S
Vaccine; 2009 Feb; 27(9):1306-16. PubMed ID: 19162111
[TBL] [Abstract][Full Text] [Related]
7. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection.
Ahuja SS; Reddick RL; Sato N; Montalbo E; Kostecki V; Zhao W; Dolan MJ; Melby PC; Ahuja SK
J Immunol; 1999 Oct; 163(7):3890-7. PubMed ID: 10490989
[TBL] [Abstract][Full Text] [Related]
10. Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice.
Rafati S; Zahedifard F; Azari MK; Taslimi Y; Taheri T
Exp Parasitol; 2008 Mar; 118(3):393-401. PubMed ID: 18093586
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis.
Carrillo E; Crusat M; Nieto J; Chicharro C; Thomas Mdel C; Martínez E; Valladares B; Cañavate C; Requena JM; López MC; Alvar J; Moreno J
Vaccine; 2008 Mar; 26(15):1902-11. PubMed ID: 18321614
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
13. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
Nagill R; Kaur S
Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
[TBL] [Abstract][Full Text] [Related]
14. Leishmania infantum FML pulsed-dendritic cells induce a protective immune response in murine visceral leishmaniasis.
Foroughi-Parvar F; Hatam GR; Sarkari B; Kamali-Sarvestani E
Immunotherapy; 2015; 7(1):3-12. PubMed ID: 25572475
[TBL] [Abstract][Full Text] [Related]
15. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
Mazumdar T; Anam K; Ali N
Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
[TBL] [Abstract][Full Text] [Related]
16. Imprinting of BALB/c mice with low Leishmania infantum parasite dose markedly protects spleen against high-dose challenge.
Ferrua B; Luci C; Le Fichoux Y; Paul A; Marty P
Vaccine; 2006 Jan; 24(5):589-96. PubMed ID: 16157427
[TBL] [Abstract][Full Text] [Related]
17. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
Tewary P; Sukumaran B; Saxena S; Madhubala R
Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Iborra S; Soto M; Carrión J; Alonso C; Requena JM
Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
[TBL] [Abstract][Full Text] [Related]
19. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis.
Rafati S; Zahedifard F; Nazgouee F
Vaccine; 2006 Mar; 24(12):2169-75. PubMed ID: 16325969
[TBL] [Abstract][Full Text] [Related]
20. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
Daifalla NS; Bayih AG; Gedamu L
Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
